CHIROPRACTIC PRACTICE ACT – Amends existing law to clarify the existing right of persons licensed to practice chiropractic to prescribe certain prescription drug products.
Summary
S1254 amends Idaho’s Chiropractic Practice Act to clarify that licensed chiropractors who are certified in clinical nutrition may prescribe and treat patients with certain limited prescription drug products already contemplated by existing law. According to the statement of purpose, the bill is intended to carry out the original intent of Idaho Code § 54-716 by ensuring chiropractors can actually obtain the limited products they are authorized to use and independently administer to patients.
The bill is framed as a clarification rather than a substantive expansion of authority. It addresses a reported access problem in which compound pharmacies and pharmaceutical distributors were not providing the relevant products to chiropractors, despite the existing statutory allowance. The fiscal note states that the measure has no General Fund impact because it only clarifies current statute.
Impact
The bill affects Idaho Code § 54-716 and related provisions governing chiropractic practice and the limited prescribing/administration authority of licensed chiropractors certified in clinical nutrition. It is designed to remove ambiguity and facilitate access to certain prescription drug products for eligible chiropractors, which may affect chiropractors, patients receiving chiropractic care, compound pharmacies, and pharmaceutical distributors. The measure became law and is effective July 1, 2026.
Sentiment
Overall sentiment appears favorable. The Senate passed the bill unanimously on third reading, and the House also approved it by a substantial margin, indicating broad legislative support for clarifying chiropractors’ access to limited prescription drug products. The absence of committee transcript material suggests there was little recorded public controversy in the available materials.
Contention
The main point of contention, to the extent reflected in the bill materials, is not the underlying chiropractic authority itself but the practical implementation problem: whether compound pharmacies and pharmaceutical distributors should be required or expected to provide the limited products to chiropractors. Supporters characterize the bill as a technical fix to restore access and effectuate existing law, while any opposition likely centered on concerns about the scope of chiropractic prescribing authority, pharmacy distribution practices, or whether the clarification could be read as expanding practice rights beyond what some stakeholders believe was originally intended.